MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 40%. Investor Relations. . stock news by MarketWatch. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Theratechnologies Inc. We also use them to share usage. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. However, only about 4% of the stocks on the OTC market fall into this category. com. 31K. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. S. Theratechnologies Inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies Inc. com uses cookies on this site. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Stockhouse. See a list of the most recent Stock Forum posts on Stockhouse. We also use them to share usage information with our partners. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. 20% from a day low at $1. Stockhouse. 08). Senior Director, Investor Relations. By continuing to use our service, you agree to our use of cookies. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. We also use them to share usage information with our partners. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. Cookies are used to offer you a better browsing experience and to. By continuing to use our service, you agree to our use of cookies. org. Focused on small-cap companies and sectors. By continuing to use our service, you agree to our use of cookies. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Stockhouse. $30. By continuing to use our service, you agree to our use of cookies. However, it did not meet the equivalence limits of 0. stock news by MarketWatch. Image source: The Motley Fool. Stockhouse. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. T. Data presented at AMCP Nexus 2023. Stockhouse. 2% for this period. By continuing to use our service, you agree to our use of cookies. Track Theratechnologies Inc. Theratechnologies Inc. 49) by $0. MONTREAL, Oct. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. com uses cookies on this site. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 's motion for leave to commence. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 0. Find the latest Theratechnologies Inc. For investor inquiries: Leah Gibson. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Last Reviewed: February 24, 2023. Further. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. We also use them to share usage information with our partners. 35 as of 10:41 a. 's motion for leave to commence. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. 46. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. 25. Their average twelve-month price target is $36. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage. com. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. T. Watch list NEW Set a price target alert After Hours Last. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. Gary Littlejohn. We currently market prescription products for people with HIV in the United States. Cookies are used to offer you a better browsing experience and to analyze our traffic. acts as investment manager. 51 to 200 Employees. 10% most volatile stocks in CA Market. 69, 1. 28 $1. MONTREAL, Aug. We also use them to share usage. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. Stockhouse. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Further. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. com uses cookies on this site. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. Theratechnologies, Inc. ET. Once expert advice is considered, the Company. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. By continuing to use our service, you agree to our use of cookies. Unveiling Silvercorp's golden potential at the Ying Mining District. The business had revenue of $27. The company develops treatments for lipodystrophy . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Market Cap. Theratechnologies Inc. A high-level overview of Theratechnologies Inc. L. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. The price has fallen in 5 of the last 10 days. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Appoints New Board Member. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. MONTREAL, Jan. Gary Littlejohn Stockhouse. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Theratechnologies Announces 1-for-4 Reverse Stock Split. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Stockhouse. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. MONTREAL, Nov. . Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. NEW YORK, Dec. 26 +15. Theratechnologies, Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 8. By continuing to use our service, you agree to our use of cookies. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. Company Description: Theratechnologies is pepped up on peptides. We currently market prescription products for people with HIV in the United States. We currently market prescription products for people with HIV in the United States. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Theratechnologies inc. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. MONTREAL, Aug. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. Who is Theratechnologies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Read More. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. MONTREAL, Jan. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. (THTX) stock. 9 million, adjusted EBITDA of $2. Stockhouse. VANCOUVER, British Columbia, Nov. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. A live webcast of Dr. 11/05/2020 4:15:02 PM. Cookies are used to offer you a better browsing experience and to analyze our traffic. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 9 million as at August 31, 2023. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Message Board Total Posts: 4. znewcar1. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. 68 to a day high of $1. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 72%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. 1-514-336-7800. 617-356-1009. Investor Relations. TH | Complete Theratechnologies Inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. US Headquarters. THERATECHNOLOGIES INC. Headquarters. When this page refreshes you will be logged in with the new address. 3. com 10/16/2023. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Trogarzo® and. Cookies are used to offer you a better browsing experience and to analyze our traffic. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 8 million. 9 million and US$19. MONTREAL, Feb. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. MONTREAL, Nov. Losses were -47. . (TH. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. Stockhouse. 60%. By continuing to use our service, you agree to our use of cookies. Q3 2023 consolidated revenue of $20. com uses cookies on this site. com uses cookies on this site. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 86 million for the quarter. T. 1M. com uses cookies on this site. stock news by MarketWatch. One reason for that is that this tier does not include penny stocks. Stockhouse. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Stockhouse. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). For investor inquiries: Leah Gibson. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. MONTREAL, Sept. THTX earnings call for the period ending February 29, 2020. (THTX) stock. MONTREAL, Feb. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. Stockhouse. Theratechnologies has generated ($1. We changed the address of the Stockhouse website from to stockhouse. Cookies are used to offer you a better browsing experience and to. W. Cookies are used to offer you a better browsing experience and to analyze our traffic. (THTX) NasdaqCM - NasdaqCM Real Time Price. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 10% least volatile stocks in CA Market. TH | March 7, 2023. (TH. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. 66% compared to the previous year's 69. Marsolais’ presentation will be available through. Theratechnologies reduces R&D head count to compensate for sales setback. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. During the last trading day the stock fluctuated 4. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our traffic. Get the latest Sernova Corp (SVA) real. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. View real-time stock prices and stock quotes for a full financial overview. Clinical-stage pharmaceutical company Theralase Technologies Inc. Currency in USD Follow 2W 10W 9M 1. stock price gained 1. Stockhouse. Theratechnologies had a negative net margin of 36. Stockhouse. Saint-Laurent, Canada. ASP | Complete Acerus Pharmaceuticals Corp. Statut du système de négociation. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. The company reported ($0. . 29(+0. 00. 9 million as at August 31, 2023. 23) earnings per share over the last year ( ($1. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). TH | May 19, 2023. Theratechnologies Inc. We also use them to. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Further. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. TH | May 19, 2023. GlobeNewswire. Stockhouse. Stockhouse. -based clinical sites participating in the conduct of the Phase. com uses cookies on this site. 51 S1. 00%. Cookies are used to offer you a better browsing experience and to analyze our traffic. H. TORONTO, May 19, 2023. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This suggests a possible upside of 2,471. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. The company had revenue of $20. Share your ideas and get valuable. We also use them to share usage. Herein, we report. MONTREAL, Feb. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. TH | September 5, 2023. MONTREAL, Oct. This news release constitutes a “designated news release” for the purposes of the Company’s. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. is an employee of TaiMed Biologics USA, Inc. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . B2Gold Declares Fourth Quarter 2023 Dividend. THERATECHNOLOGIES INC. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Visit the TSX ETF Investor Centre to access our screener and comparison tool. We also use them to share. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. By continuing to use our service, you agree to our use of cookies.